AU5816596A - Pharmaceutical administration form of parathyroid hormone ha ving an active ingredient release period of from two to six hours - Google Patents

Pharmaceutical administration form of parathyroid hormone ha ving an active ingredient release period of from two to six hours

Info

Publication number
AU5816596A
AU5816596A AU58165/96A AU5816596A AU5816596A AU 5816596 A AU5816596 A AU 5816596A AU 58165/96 A AU58165/96 A AU 58165/96A AU 5816596 A AU5816596 A AU 5816596A AU 5816596 A AU5816596 A AU 5816596A
Authority
AU
Australia
Prior art keywords
ving
hours
active ingredient
parathyroid hormone
administration form
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU58165/96A
Other languages
English (en)
Inventor
Bernd Muller-Beckmann
Peter-Paul Ochlich
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Roche Diagnostics GmbH
Original Assignee
Boehringer Mannheim GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Mannheim GmbH filed Critical Boehringer Mannheim GmbH
Publication of AU5816596A publication Critical patent/AU5816596A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
AU58165/96A 1995-05-12 1996-05-09 Pharmaceutical administration form of parathyroid hormone ha ving an active ingredient release period of from two to six hours Abandoned AU5816596A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19517430A DE19517430A1 (de) 1995-05-12 1995-05-12 Pharmazeutische Darreichungsform von Parathormon mit einer zwei- bis sechsstündigen Wirkstoff-Freisetzungsperiode
DE19517430 1995-05-12
PCT/EP1996/001962 WO1996035447A1 (en) 1995-05-12 1996-05-09 Pharmaceutical administration form of parathyroid hormone having an active ingredient release period of from two to six hours

Publications (1)

Publication Number Publication Date
AU5816596A true AU5816596A (en) 1996-11-29

Family

ID=7761731

Family Applications (1)

Application Number Title Priority Date Filing Date
AU58165/96A Abandoned AU5816596A (en) 1995-05-12 1996-05-09 Pharmaceutical administration form of parathyroid hormone ha ving an active ingredient release period of from two to six hours

Country Status (7)

Country Link
EP (1) EP0825872A1 (de)
JP (1) JPH11505222A (de)
AU (1) AU5816596A (de)
DE (1) DE19517430A1 (de)
IL (1) IL118202A0 (de)
WO (1) WO1996035447A1 (de)
ZA (1) ZA963714B (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0922467A3 (de) 1997-12-12 2000-05-24 Takeda Chemical Industries, Ltd. Iontophoretische Verabreichung von Medikamenten
US8088734B2 (en) 2003-01-21 2012-01-03 Unigene Laboratories Inc. Oral delivery of peptides
CN101355959B (zh) 2005-11-10 2013-02-27 密歇根理工大学管理委员会 黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
CA2782640A1 (en) 2009-12-07 2011-06-16 Michigan Technological University Black bear parathyroid hormone and methods of using black bear parathyroid hormone
ME02474B (de) 2010-05-12 2017-02-20 Radius Health Inc Therapiepläne
BR112013007685B1 (pt) 2010-09-28 2021-11-09 Radius Pharmaceuticals, Inc Compostos moduladores de receptor andrógeno seletivos, composição farmacêutica compreendendo os referidos compostos, método de identificação de um composto capaz de modular um receptor andrógeno, usos de um composto ou da composição e processo para a preparação de um composto
IL297369B1 (en) 2015-04-29 2024-02-01 Radius Pharmaceuticals Inc RAD for use in a method to treat mutant estrogen receptor positive breast cancer or mutant estrogen receptor positive ovarian cancer
RU2769527C2 (ru) 2016-06-22 2022-04-01 Эллипсес Фарма Лтд Способы лечения ar+ рака молочной железы
KR102322802B1 (ko) 2017-01-05 2021-11-04 래디어스 파마슈티컬스, 인코포레이티드 Rad1901-2hcl의 다형 형태
US11643385B2 (en) 2018-07-04 2023-05-09 Radius Pharmaceuticals, Inc. Polymorphic forms of RAD1901-2HCl

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4692433A (en) * 1983-10-12 1987-09-08 The Regents Of The University Of California Method and composition for regulating serum calcium levels of mammals
DE3935738A1 (de) * 1989-10-27 1991-05-08 Forssmann Wolf Georg Arzneimittel, enthaltend das humane parathormon-fragment (1-37) als aktiven wirkstoff
EP0643981B1 (de) * 1993-09-22 2002-01-09 Hisamitsu Pharmaceutical Co., Inc. Iontophoresematrix

Also Published As

Publication number Publication date
JPH11505222A (ja) 1999-05-18
DE19517430A1 (de) 1996-11-14
IL118202A0 (en) 1996-09-12
ZA963714B (en) 1997-11-10
WO1996035447A1 (en) 1996-11-14
EP0825872A1 (de) 1998-03-04

Similar Documents

Publication Publication Date Title
HUP0004383A2 (hu) Hatóanyagként klodronátot és vivőanyagként szilíciumozott mikrokristályos cellulózt tartalmazó gyógyszerészeti készítmény
CA2033725A1 (en) Pharmaceutical and cosmetic compositions containing a salt of cholanic acid
EP0727217A3 (de) Pharmazeutische und kosmetische Zusammensetzungen enthaltend God-Typ-Ellagitannin als Wirkstoff
HUT64065A (en) Process for producing quinolone- and naphthyridonecarboxylic acid derivatives and pharmaceutical compositions comprising same as active ingredient
HUT51254A (en) Process for producing amino acid derivatives and pharmaceutical compositions comprising same as active ingredient
IE894048L (en) New therapeutically active compound and a process for its¹preparation
HUT60466A (en) Process for producing amino acid derivatives and pharmaceutical compositions comprising such active ingredient
CA2329005A1 (en) Folic acid-containing pharmaceutical compositions, and related methods and delivery systems
CA2213989A1 (en) External preparation for topical administration
AU7305594A (en) Physiologically active substance-prolonged releasing-type pharmaceutical preparation
AU4338099A (en) Pharmaceutical composition containing a salt of acetaminophen and at least one other active ingredient
HUP9901457A3 (en) Three-phase pharmaceutical form with constant and controlled release of amorphous active ingredient for single daily application
HUT59314A (en) Process for producing pharmaceutical composition comprising minocylcine active ingredient and suitable for a single daily administration
CA2251886A1 (en) An oral pharmaceutical formulation containing ibandronate
CA2232855A1 (en) Pharmaceutical formulation
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
HUT58060A (en) Process for producing amino acid derivatives and pharmaceutical compositions comprising such active ingredient
AU5254296A (en) Anthelmintic use of nodulisporic acid and analogs thereof
AU7294196A (en) Stable pharmaceutical forms of administration containing parathormone
AU5816596A (en) Pharmaceutical administration form of parathyroid hormone ha ving an active ingredient release period of from two to six hours
AU4560297A (en) Pharmaceutical microspheres of valproic acid for oral administration
AU2773597A (en) Pharmaceutical compositions for the sustained release of insoluble active principles
CA2348474A1 (en) Pharmaceutically active composition and dispensing device
IL115125A0 (en) Pharmaceutical formulations comprising derivatives of clavulanic acid
HUT47127A (en) Process for producing pyrimidine derivatives and pharmaceutical compositions comprising such active ingredient